Fig. 7: MEC exhibits no adverse interaction with anti-TB drugs.
From: Bioenergetic reprogramming of macrophages reduces drug tolerance in Mycobacterium tuberculosis
A Three groups of treatment in BALB/c mice used in the pharmacokinetic study: MEC alone, front-line anti-TB combination therapy (HREZ), and combination (MEC + HREZ); B–F Line plots indicate pharmacokinetic profiles of MEC and individual drugs of the anti-TB therapy regimen, analyzed individually and in the presence of each other in the plasma of animals. Differences were non-significant by the two-tailed Mann-Whitney test (p > 0.05). G Ratios of Cmax and AUClast of individual drugs or a combination with MEC to analyze drug-drug interactions. Doses used are the following: MEC, 25 mg/kg body weight, ip; H, 25 mg/kg body weight, per os (po); R, 10 mg/kg body weight, po; E, 200 mg/kg body weight, po; Z, 150 mg/kg body weight, orally; BDL, below the detection limit. All data are means ± S.D. of concentrations at each time point of samples in triplicate (n = 3 animals per group), H Lung deposition of MEC alone and combined with anti-TB drugs at 6 h and 24 h post-ip administration. Source data are provided as a Source Data file.
